Articles tagged with Poliovirus
A study from UMBC reveals a conserved RNA-protein interaction as a promising target for broad-spectrum enterovirus antivirals. The researchers found that a fusion protein called 3CD recruits proteins to assemble the replication complex, and targeting this interface could lead to universal drugs.
Researchers at the University of Leeds have developed a more affordable and lower-risk polio vaccine using virus-like particles (VLPs). VLPs mimic the outer protein shell of poliovirus but are empty inside, making them non-infectious yet capable of triggering an immune response.
The EU/EEA has detected circulating vaccine-derived poliovirus type 2 (cVDPV2) in sewage samples, prompting increased vigilance. To prevent a return of the disease, countries must maintain high vaccination rates and close vaccination gaps, as well as strengthen environmental surveillance.
A high number of poliovirus detections in European countries has highlighted the importance of maintaining high vaccination coverage. The virus can be imported into Europe as long as it circulates globally, posing a risk to unvaccinated populations.
Researchers at Rice University have developed a time-release technology called PULSED that could help protect against poliomyelitis in combination vaccines. The technology would allow poliovirus-like particles to be released from microparticles after a few days, ensuring full vaccination efficacy.
Scientists at UCSF and NIBSC have developed two new oral polio vaccines with genetically engineered weakened poliovirus to reduce reversion to dangerous forms. These vaccines aim to boost the World Health Organization's efforts to eradicate polio, which has persisted despite successful international vaccination campaigns.
Global virus network experts propose changes to global polio eradication strategy, emphasizing the need for high vaccination coverage and adaptable policies. They suggest using both inactivated and live, weakened vaccines, as well as reconvening a scientific advisory group to respond to new data and public health emergencies.
Global immunization efforts have made polio a rare disease, but healthcare workers still need to be vigilant for acute flaccid paralysis. Dr. Marina Salvadori emphasizes the importance of alerting healthcare workers to this diagnosis as elimination is within reach.
Poliovirus researchers at Umeå University have gained a new understanding of how the virus behaves in infected cells, revealing key protein roles and cellular processes involved. This breakthrough could lead to the development of new antiviral treatments and vaccines targeting the autophagy system.
A polio outbreak risk has been heightened in western Ukraine due to the reintroduction of wild-type poliovirus and low immunization rates. The situation has worsened with the COVID-19 pandemic, ongoing war, and healthcare reforms, leading to a public health emergency declaration.
The study suggests that COVID-19 eradication is technically possible due to the availability of safe vaccines, lifelong immunity, and effective government management. However, securing high vaccine coverage and responding quickly to variants are major challenges.
The global polio eradication initiative is facing setbacks due to ongoing outbreaks in Afghanistan and Pakistan, despite significant progress made since 2015. The recent special issue of Risk Analysis evaluates the GPEI strategies and finds that the initiative was off track even before the COVID-19 pandemic disrupted immunization activ...
A team from the Universities of York and Leeds has identified the way viruses like poliovirus and common cold virus assemble infectious copies of their genetic material. The study's findings could lead to the development of drugs that can block viral infections.
A new poliovirus vaccine has been developed to combat a mutated strain linked to outbreaks in Africa and Asia. The vaccine, known as nOPV2, has shown similar immune responses and improved genetic stability compared to the licensed Sabin oral vaccine.
A genetic study of the live polio vaccine has identified critical mutations that allow the virus to evolve into a more virulent form, posing a risk to eradication efforts. However, the study also found that these changes are not easily transmitted from person to person.
A new oral poliovirus vaccine is urgently needed due to ongoing mutant polio outbreaks. The current OPV2 formulation's continued use contributes to transmission and outbreaks, prompting the need for a novel serotype 2 vaccine.
Researchers at Duke University Medical Center have developed a poliovirus-based therapy that stimulates a natural immune attack on cancer cells in animal studies. The modified virus, called PVSRIPO, induces an immune response against mutated cancer cells found in diffuse midline glioma tumors, which are universally deadly in children.
A genetically modified poliovirus therapy developed at Duke Cancer Institute has shown significantly improved long-term survival for patients with recurrent glioblastoma, with a three-year survival rate of 21 percent. The therapy preferentially targets tumor cells and ignites a targeted immune response.
A recent study published in Scientific Reports has shown that the Nanopatch, a microscopic vaccine delivery platform, is more effective at combating poliovirus than traditional needles and syringes. This breakthrough has significant implications for the eradication of polio, a disease responsible for tens of millions of cases worldwide.
A modified poliovirus therapy has been found to induce an inflammation process that counteracts cancer cells' ability to evade the immune system. The therapy activates dendritic cells and macrophages, which present tumor antigens to T-cells, launching a targeted immune response.
Scientists at the John Innes Centre have produced a new vaccine against poliovirus using virus-like particles grown in plants. The vaccine uses a method that employs virus-like particles (VLPs) - non-pathogenic mimics of poliovirus which are grown in plants.
Researchers like Dr. Julie Pfeiffer are studying poliovirus, a highly infectious childhood disease now close to global eradication, to gain insights into other viruses like Ebola, Zika, and influenza. This basic research can lead to new treatments and vaccines for these viruses.
A research team at the University of Leeds has identified new mutations that make 'empty capsids' stable enough to act as vaccines, replacing traditional killed poliovirus vaccines. The stabilised VLPs are suitable for use after the virus has been eradicated and can be produced without growing live virus.
Researchers have developed a new method to produce stable poliovirus protein shells, which can be used as vaccines and do not require growing live viruses. The shells have been shown to induce high levels of protective antibodies in mice and rats.
A new study using disease-transmission models shows that silent transmission of poliovirus could continue for more than three years with no reported cases. To ensure eradication, aggressive surveillance and vaccination campaigns must continue in endemic countries after the last reported case.
A new study suggests that combining Salk inactivated poliovirus vaccine (IPV) with Sabin live-attenuated oral poliovirus vaccine (OPV) improves mucosal immunity and reduces viral shedding. The results could help resolve the long-standing debate over vaccine choice in areas where polio is difficult to eradicate.
Giving children under 5 an extra dose of inactivated polio vaccine (IPV) boosts their immunity to the poliovirus, supporting global eradication efforts. The additional dose substantially improves protective antibodies and intestinal immunity against poliovirus.
Researchers identified a polio-like syndrome in five California children over a year, highlighting the possibility of an emerging infectious polio-like syndrome. The children experienced paralysis affecting one or more limbs with abnormal MRI scans, and two tested positive for enterovirus-68.
A new study found that sharp declines in vaccine uptake led to an increase in polio cases in Afghanistan and Pakistan. The introduction of more effective vaccines has proven ineffective without sufficient coverage, highlighting the need for improved vaccination programs to eradicate polio globally.
A Tel Aviv University researcher warns that live virus polio vaccine evolution can continue to threaten global eradication efforts. The expert recommends maintaining herd immunity, environmental surveillance, and switching to inactivated vaccines.
A new bivalent oral vaccine against poliovirus types 1 and 3 has been found to be more immunogenic than current vaccines, inducing a stronger immune response in newborn babies. The vaccine's effectiveness is comparable to that of the existing monovalent and trivalent vaccines, offering enhanced immunity for both virus types.
A new study has shown that a vaccine-derived strain of poliovirus can be as easily transmitted and likely to cause severe disease as wild-type poliovirus. Vaccination with trivalent OPV is highly effective in preventing paralysis by this serotype 2 cVDPV, making it crucial for efforts to eradicate polio continue.
Researchers at Purdue and Stony Brook universities have determined the precise atomic-scale structure of the poliovirus attached to key receptor molecules in human host cells. The study provides a detailed analysis of how a virus can enter its host cell, shedding light on infection processes.
Scientists have discovered that an attenuated form of poliovirus can effectively destroy neuroblastoma tumors in mice without harming them. The study's findings suggest that this approach could represent a new, safe means of treating childhood cancer and potentially other cancers in adults.
A 2004 China polio outbreak caused by vaccine-derived virus was identified and controlled after a province-wide immunization campaign. The outbreak occurred in an area with lower vaccination rates, highlighting the risk of vaccine-derived poliovirus emergence in pockets of low coverage.
Researchers found that two doses of inactivated polio vaccine (IPV) provided similar immunity to one dose of the live virus vaccine. However, IPV's mucosal immunity was less effective than OPV's. The study suggests that HPV-immunized communities are partially protected from poliovirus spread.
A study by Duke University Medical Center found that Coxsackievirus A21 can cause polio-like symptoms in genetically engineered mice, as it bypasses the usual nasal cavity route and infects muscle cells instead. The findings have significant implications for the understanding of viral behavior and potential vaccine development.
Researchers created a modified poliovirus that targets and destroys cancer cells in the brain, but spares normal brain tissue. The virus uses a rhinovirus genetic element to trigger gene expression in cancer cells, but malfunctions in normal neurons due to lack of co-factors.
A Danish study found that individuals exposed to contaminated poliovirus vaccine had no increased risk of cancer compared to those not exposed. The findings contradict previous laboratory and epidemiologic evidence suggesting a link between SV40 contamination and human cancer.
A study found no significant association between exposure to contaminated poliovirus vaccine and the incidence of pleural mesothelioma, a rare lung cancer. Incidence rates increased among older males, but remained stable or decreased in younger age groups.
A research group from Purdue University analyzed the interaction between poliovirus and its receptor, finding that it uses a similar site to bind as human rhinoviruses. The study provides new insights into how viruses selectively attach to receptors and may suggest ways for developing drugs to prevent illnesses caused by viral pathogens.